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Abstract 
The implantation of a penile prosthesis is still the ultima ratio for patients with 
erectile dysfunction who fail other treatment options such as pharmacothera-
py and penile venous surgery. Despite mostly favorable results regarding res-
tauration of erectile capacity, penile allografts are often not accepted for var-
ious reasons. Therefore, pharmacotesting with a mixture of calcitonin gene-
related peptide and prostaglandin Ei (CGRP/PGEi) was offered to different 
selected patients populations: 28 patients with erectile dysfunction and 
venous leakage who failed penile venous surgery, 28 patients with erectile dys-
function and venous leakage (who refused penile venous surgery) and 12 
patients without venous leakage, but poor response to maximum doses of 
papaverine/phentolamine, received 5 jig CGRP plus 10 jig PGE^ Erections 
sufficient for intercourse were noted in 19/28 (67.9%), 20/28 (71.4%) and 11/ 
12 (91.7%) patients, respectively. Our data show that a combination of CGRP 
and PGEi may be an alternative to penile implants in selected patients. 
Introduction 
Cavernous smooth muscle tissue plays a major role in 
the induction and maintenance of a normal erection [1, 
2]. In addition to adequate arterial inflow, relaxation of 
the cavernous smooth muscle is required, resulting in a 
strong reduction of venous outflow. Theoretically, insuffi-
cient venous outflow reduction can be caused by ectopic 
veins, incomplete cavernous relaxation or pathologic al-
terations of the tunica albuginea [3-5]. Standardized 
intracavernous pharmacotesting has been shown to be of 
high predictive value for the diagnosis of venous leakage 
[6]. However, in some patients not responding to repeti-
tive maximum doses of conventional pharmacotherapy, 
no venous leakage is found by cavernosometry and caver-
nosography. In these patients the etiology of impotence 
remains obscure and cannot be assessed by current diag-
nostic tests when arterial disease has been ruled out. 
In patients with venous leakage, penile venous surgery 
is a common treatment option. However, despite increas-
ing knowledge about the pathomechanism of venoocclu-
sive dysfunction, the results of venous ligation procedures 
often remain dissatisfying. The ultima ratio for patients 
who fail penile venous surgery and who do not respond to 
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conventional pharmacotherapy is still the implantation of 
a penile prosthesis. 
This study was undertaken to identify therapeutic 
alternatives for patients who failed penile venous surgery, 
who do not respond to conventional pharmacotherapy or 
who refuse penile allografts for various reasons. 
Patients and Methods 
The routine workup of patients with erectile dysfunction in our 
impotence clinic consists of a detailed case history including a ques-
tionnaire, a sexual case history by a psychiatrist where indicated, a 
complete physical examination, routine blood laboratory, corpus 
cavernosum electromyography [7], pharmacotesting with a mixture 
of papaverine and phentolamine and Doppler ultrasonography. 
Where indicated, pharmacocavernosometry/-graphy and digital sub-
traction angiography are done. 
Pharmacotesting was done in a relaxed atmosphere after in-
formed consent had been obtained. Increasing doses of a mixture of 
papaverine (15 mg/ml) and phentolamine (0.5 mg/ml) were given, 
starting with a dose of 0.2 ml. Only 1 injection per day was given to 
avoid prolonged erections. The dose was increased to a maximum of 
2.0 ml depending on the erectile response. Erections were evaluated 
by a urologist by inspection and palpation and graded as follows: 
E 0 = no response; E 1 = slight tumescence; E 2 = medium tumes-
cence; E 3 = full tumescence; E 4 = full tumescence with medium 
rigidity sufficient for intercourse, E 5 = full erection. If 2 ml of the 
mixture failed to induce an erection sufficient for intercourse despite 
additional manual self-stimulation, venous leakage was suspected 
and the patient was offered pharmacocavernosometry/-graphy for 
evaluation of the venoocclusive system. 
For corpus cavernosum electromyography (the term SPACE -
single potential analysis of cavernous electrical activity - was aban-
doned in favor of the more precise and neutral term CC-EMG - cor-
pus cavernosum electromyography - by the consensus committee at 
the First International Workshop on Smooth Muscle EMG Record-
ings/Leimyogram in Mannheim/FRG) [8] 2 coaxial needle electrodes 
(Dantec 9013 L) were inserted bilaterally into the cavernous bodies 
and advanced until the tips of the electrodes were located centrally. 
The signals were processed by different electrophysiological units 
(WIEST SPACE, Dantec Neuromatic 2000), displayed continuously 
on a monitor screen (Dantec 2000) and simultaneously recorded 
(WIEST SPACE). Interpretation of the recordings was done accord-
ing to previously published data [7]. Since 9/92 EMG signals were 
recorded on-line with a personal computer and data were processed 
using an especially designed software on the basis of the Fast-Fourier 
analysis [9]. 
Doppler ultrasonography of the penile arteries was performed as 
described elsewhere [10]. For pharmacocavernosometry/-graphy the 
left corpus cavernosum was punctured with a 19-gauge needle under 
sterile conditions and connected to a perfusion pump. The right cor-
pus cavernosum was punctured with a 26-gauge needle and con-
nected to a transducer for pressure recording (WIEST Cavopump, 
Wiest, Germany). To induce cavernous smooth muscle relaxation, 
30 mg of papaverine and 1 mg of phentolamine were injected intra-
cavernously via the left cannula. After 10 min and subsequent to cav-
ernous relaxation, cavernosometry was performed by perfusing the 
penis with warm (37 °C) saline with a flow rate of 150 ml/min. As 
soon as rigidity was reached, the minimum flow to maintain a full 
erection was determined ('maintenance flow'). After infusion of 
undiluted nonionic contrast medium, X-ray films were taken in ante-
roposterior and oblique (30°) positions. After opacification, the penis 
was perfused with normal saline to wash out the contrast medium. 
The needles were removed and the puncture sites were compressed 
manually. Flow rates exceeding 14 ml/min were considered abnor-
mal [11-13]. 
All 129 patients with documented venous leakage were offered 
penile venous surgery and counseled about alternative therapeutic 
options. 
Penile venous surgery was done as follows: A midline incision 
was done over the dorsum of the penis, then the superficial dorsal 
veins were ligated and the deep dorsal veins were resected from about 
1 cm proximal to the suspensory ligament to the distal l/3 of the 
penile shaft. 
Since previous studies showed a higher response rate of a combi-
nation of calcitonin gene-related peptide (CGRP) plus prostaglandin 
E[ (PGEi) as compared to PGEi alone [14], we offered this combina-
tion (5 jig CGRP plus 10 jig PGEi) to patients with venous leakage 
who failed penile venous surgery, to patients with venous leakage 
who refused penile venous surgery and to patients without docu-
mented venous leakage who failed pharmacotherapy with papaver-
ine/phentolamine. Prior to the injections all patients were extensive-
ly informed about the experimental character of this drug combina-
tion as well as possible side effects. The study protocol was approved 
by the Ethics Committee of the Medizinische Hochschule Hanno-
ver. 
Results 
After a comprehensive workup including pharmaco-
testing, venous leakage was suspected in 160/448 patients 
(35.7%). Insufficiency of the venoocclusive system was 
diagnosed in 129/160 (80.6%) or 129/448 (28.8%) pa-
tients, respectively. As therapeutic options penile venous 
surgery, implantation of a penile prosthesis, the use of a 
vacuum constriction device or a trial with CGRP/PGEi 
injections were offered. After extensive counselling, 84 
patients underwent penile venous surgery, 28 patients 
opted for a trial with CGRP/PGE!, 5 patients (all with 
concomitant Peyronie's disease) underwent implantation 
of a penile prosthesis and 2 patients with dysplastic arteri-
al disease underwent arterial revascularization and penile 
venous surgery. The use of a vacuum constriction device 
was favored by 5 patients. The remaining 5 patients are 
either awaiting or refused further therapy (table 1). 
In 31/160 patients (19.4%) without adequate response 
to 30 mg papaverine plus 1 mg phentolamine, venous 
leakage could not be documented by cavernosometry and 
-graphy. 28 patients who failed penile venous surgery 
underwent pharmacotesting with 5 jig CGRP plus 10 jig 
PGEi. Of these, 19 (67.9%) achieved erections sufficient 
41 
Table 1. First-line management in 129 patients with erectile dys-
function and venous leakage 
Penile venous surgery 84 
CGRP/PGEi trial 28 
Implantation of penile prosthesis 5 
Vacuum constriction device 5 
Arterial reconstruction (Hauri) and penile venous surgery 2 
Awaiting therapy or refused treatment 5 
Values are number of patients. 
for intercourse. In addition, 28 patients with venous leak-
age who refused penile venous surgery and 12 nonrespon-
ders to papaverine/phentolamine (but without venous 
leakage) opted for pharmacotesting with CGRP/PGEj. 
20/28 (71.4%) and 11/12 (91.7%) patients had E 4 or E 5 
responses. In the latter highly selected population the eti-
ology of erectile dysfunction remained unclear despite a 
thorough diagnostic workup (significant arterial disease 
had been ruled out by Doppler ultrasonography). 
The patients who responded to pharmacotherapy with 
CGRP/PGEi entered another study to evaluate the safety 
and efficacy of CGRP/PGEi autoinjection therapy. Up to 
now no significant side effects have been reported in this 
group after up to 80 and more autoinjections per patient 
[14]. Only 2/40 patients (5.0%) reported significant intra-
penile pain associated with the injection. 
A total of 13 patients (after failed penile venous sur-
gery and/or failed CGRP/PGEi pharmacotesting) under-
went implantation of penile allografts and 10 patients 
opted for a vacuum constriction device. The remaining 
patients refused further treatment. 
Discussion 
The management of erectile dysfunction associated 
with or due to venous leakage is far from being standard-
ized despite better diagnostic tests to evaluate the etiology 
of impotence. As demonstrated in previous studies [6], 
standardized pharmacotesting with vasoactive substances 
was shown to have a high predictive value for the evalua-
tion of the venoocclusive system. Although short-term 
results of the presumably causative therapy, penile ve-
nous surgery, often seemed to be promising [15], the out-
come with longer follow-up tends to be disappointing 
[16]. Concomitant arterial disease was claimed to be one 
of the predisposing factors for the failure of venous sur-
gery and, therefore, reconstructive vascular surgery was 
promoted with various intermediate and long-term re-
sults [17, 18]. Incomplete cavernous relaxation due to 
autonomic dysfunction or myogenic cavernous degenera-
tion may be one of the possible etiologies of the insuffi-
ciency of the venoocclusive system [19]. Since CC-EMG 
was shown to be a minimally invasive and reproducible 
method for the evaluation of autonomic cavernous inner-
vation and cavernous smooth muscle integrity [7], we 
evaluated our patient population after penile venous sur-
gery in retrospect. Of the 38 patients who failed penile 
venous surgery, 30 (78.9%) had abnormal CC-EMG pat-
terns, whereas 30/39 patients (76.9%) who had sufficient 
erections with or without additional intracavernous injec-
tions, had normal CC-EMG patterns. This difference was 
statistically highly significant (p < 0.001, %2 test) [own 
unpubl data]. Thus, routine CC-EMG evaluation in pa-
tients with erectile dysfunction and venous leakage con-
tributes significant predictive information and may alter 
the decision making in this patient population. 
The ultima ratio after failed venous surgery and con-
ventional pharmacotherapy remains the implantation of 
a penile prosthesis. However, despite mostly favorable 
results, many patients reject allografts for various reasons. 
In our experience, many patients also do not accept vacu-
um constriction devices due to their cumbersome han-
dling. Since the classical drugs for autoinjection therapy 
(papaverine, papaverine plus phentolamine, PGEj) in-
duce a full erection in only 50-70% of an unselected pop-
ulation [20-25], newer, more potent substances or mix-
tures with a higher response rate are needed [26]. CGRP, 
along with other substances, was shown to play a possible 
role in the regulation of the smooth muscle tone [27]. Pre-
liminary data show that a combination of CGRP and 
PGEi has a higher response rate than PGEi alone, with 
less side effects, such as intrapenile pain [28]. The pain 
reducing effect of CGRP/PGEi may be due to the anti-
inflammatory effect of CGRP [29] and the reduced dose 
of PGEi. We therefore offered, after extensive counseling 
about possible risks and side effects and after informed 
consent had been obtained, this combination to patients 
after failed penile venous surgery or as an alternative to 
penile venous surgery. In addition, patients without 
venous leakage as documented by cavernosometry and 
cavernosography but insufficient response to maximum 
doses of papaverine/phentolamine (despite the absence of 
significant arterial disease) were offered this drug combi-
nation. In these highly selected patient populations drugs 
with a higher erectile potential than papaverine/phentol-
amine or PGEi are needed. Pharmacotesting with CGRP/ 
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Fig. 1 . Erectile dysfunction - current managenent at Medizinische Hochschule Hannover. VCD = Vacuum con-
striction device; PP = penile prosthesis: PVS = penile venous surgery. 
PGEi induced sufficient erections in 67.9, 71.4 and 
91.7% of patients, respectively. 
The higher response rate of CGRP/PGEi compared to 
papaverine, papaverine/phentolamine or prostaglandin 
alone may be explained by the different and potentially 
additive effector mechanisms of CGRP and PGEi. 
CGRP relaxes smooth muscle cells by hyperpolarization 
via potassium channel opening and cyclic adenosine 
monophosphate stimulation [30, 31]. PGEi acts through 
specific receptors on the smooth muscle cell surface. 
In an ongoing study, the long-term efficacy and safety 
of this drug combination was evaluated with promising 
results; so far, no significant complications such as pro-
longed erections or fibrosis were noted after up to 80 and 
more injections per patient [14]. We therefore think that 
CGRP/PGEi may be a valuable alternative to penile 
implants as well as vacuum constriction devices in select-
ed patients. However, it should be stressed that the exper-
imental and clinical experience with this drug combina-
tion is still relatively limited. Despite favorable data, the 
use of CGRP/PGEi should currently be restricted to 
selected patients in well controlled clinical studies. For 
example, no data are yet available regarding the possible 
risk of prolonged erections in patients also responding to 
fess potent substances like papaverine or prostaglandin 
done. In addition, toxicological data for CGRP are 
restricted to the rabbit model, where human CGRP 
caused signs of slight to moderate inflammation [own 
unpubl. data]. Taken this together, the use of intracaver-
IOUS CGRP/PGEi in patients with impotence should still 
be regarded as experimental and patients should be made 
aware of the experimental character of this treatment 
option. 
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The therapy of erectile dysfunction is nowadays too 
complex that it possibly could be a one-strategy or even a 
one-drug therapy. The increasing complexity of the etiolo-
gies and diagnostic modalities of erectile dysfunction 
requires the availability of drugs with different effector 
mechanisms and different erectile potentials. Currently, 
we recommend different substances to different patient 
populations: For a standardized dose response we use a 
mixture of papaverine and phentolamine. In case a pa-
tient responds very well or with a prolonged erection to 
small doses of this combination (<0.7 ml), we offer the 
nitric oxide donor linsidomin chorhydrate (SIN 1) [32]. 
The efficacy of this substance has been shown to be excel-
lent in this patient population and no prolonged erections 
have been observed so far in more than 100 patients. In 
contrast, in patients who needed higher doses of papaver-
ine/phentolamine (>0.7 ml) for the induction of an erec-
tion, the efficacy was significantly lower. These data dem-
onstrate that SIN 1 is less potent but safer than papaver-
ine/phentolamine [33]. Therefore, patients who respond 
well to moderate to maximum amounts or papaverine/ 
phentolamine (0.8-2.0 ml) are maintained on this combi-
nation. 
All other patients are offered cavernosometry and cav-
ernosography and counseled about the possible alterna-
tives: penile venous surgery, use of a vacuum constriction 
device, implantation of a penile prosthesis and autoinjec-
tion therapy with CGRP/PGEj (fig. 1). As stated before, 
CGRP/PGEi should currently not be regarded as a first-
line treatment for an unselected patient population but 
should be considered for patients who need a more potent 
smooth muscle relaxing substance. 
The finding 'venous leakage' may be a symptom of 
multifactorial etiology consisting of arterial, autonomic, 
myogenic, and venogenic pathology. Thus, evaluation of 
the autonomic cavernous innervation and smooth muscle 
intactness by CC-EMG provides additional predictive 
information in regard to the outcome of venous surgery. 
Based on the data of this study, we now routinely counsel 
our patients with erectile dysfunction and venous leakage 
and offer alternatives to penile venous surgery, such as 
pharmacotherapy with CGRP/PGEi, use of a vacuum 
constriction device and implantation of a penile prosthe-
sis. 
In conclusion, our data show that success of penile 
venous surgery depends on proper patient selection; rou-
tine CC-EMG contributes significant predictive informa-
tion in patients with erectile dysfunction and venous leak-
age. The combination of CGRP and PGEi, as well as oth-
er possible substances or combinations of substances, may 
prove to be a valuable option in highly selected patients. 
Due to the experimental nature of new drug regimen, 
patients should be followed closely. 
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